Valuation: GENFIT

Market Cap 686M 795M 646M 587M 1.1B 76.14B 1.12B 7.57B 2.97B 38.08B 2.98B 2.92B 127B P/E 2026 *
35.4x
P/E 2027 * 91.1x
Enterprise Value 635M 735M 598M 543M 1.02B 70.47B 1.04B 7.01B 2.75B 35.24B 2.76B 2.7B 117B EV / Sales 2026 *
6.34x
EV / Sales 2027 * 5x
Free-Float
86.89%
Yield 2026 *
-
Yield 2027 * -
1 day+48.37%
1 month+48.37%
3 months+68.43%
6 months+98.63%
Current year+165.83%
1 month 15.95
Extreme 15.95
15.95
Current year 7.26
Extreme 7.26
15.95
1 year 4.14
Extreme 4.14
15.95
3 years 2.95
Extreme 2.95
15.95
5 years 2.95
Extreme 2.95
15.95
10 years 0
Extreme 0
36.86
Manager TitleAgeSince
Chief Executive Officer 58 16/09/2019
Director of Finance/CFO 52 22/04/2021
Chief Tech/Sci/R&D Officer - 27/11/2025
Director TitleAgeSince
Chairman 70 16/06/2017
Director/Board Member 54 15/09/1999
Director/Board Member 58 16/06/2017
Change 5-day change 1-year change 3-year change Capi.($)
+48.37%-.--% - - 804M
-0.11%-2.38%+2.06%+19.57% 48.84B
+1.89%+5.08%+492.59%+629.24% 45.44B
+1.83%+2.75%+15.61%+91.22% 41.22B
-0.50%-1.56%+24.67%+12.17% 39.71B
-2.74%-2.74%+17.30%+56.10% 32.6B
+0.59%-2.25% - - 16.25B
-1.14%-2.51%+27.52%+136.42% 16.67B
-0.49%-0.54%+2.96%+27.12% 14.08B
-2.60%-1.00%+77.85%+40.37% 13.68B
Average +4.51%-0.78%+82.57%+126.53% 29.83B
Weighted average by Cap. +0.12%-0.84%+104.01%+153.93%

Financials

2026 *2027 *
Net sales 100M 116M 94.27M 85.68M 161M 11.12B 164M 1.11B 433M 5.56B 436M 426M 18.52B 124M 144M 117M 106M 200M 13.76B 202M 1.37B 537M 6.88B 539M 528M 22.92B
Net income 22.88M 26.49M 21.53M 19.56M 36.8M 2.54B 37.34M 252M 98.95M 1.27B 99.45M 97.29M 4.23B 6.8M 7.87M 6.4M 5.81M 10.94M 754M 11.1M 75.05M 29.41M 377M 29.56M 28.92M 1.26B
Net Debt -51.12M -59.18M -48.09M -43.71M -82.21M -5.67B -83.42M -564M -221M -2.84B -222M -217M -9.45B -66.17M -76.62M -62.26M -56.59M -106M -7.34B -108M -730M -286M -3.67B -288M -281M -12.23B
Logo GENFIT
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Employees
161
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
13.88EUR
Average target price
15.90EUR
Spread / Average Target
+14.55%

Quarterly revenue - Rate of surprise